Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Calidi BiotherapeuticsCLDI +2.59%11 Operating Cash Flow per Share is $-34.45 as of Jun. 2026. GuruFocus rates CLDI with a GF Score™ of 11/100. The stock has 1 warning sign investors should review. Among 1,134 Biotechnology companies, Calidi Biotherapeutics ranks better than 86.24% on this metric.
Calidi Biotherapeutics's operating cash flow per share for the
three
months ended in Jun. 2026 was $-3.07.
Calidi Biotherapeutics's operating cash flow per share for the trailing twelve months (TTM) ended in Jun. 2026 was $-34.45.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 51.50% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 10.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for Calidi Biotherapeutics's Operating Cash Flow per Share or its related term are showing as below:
CLDI'
s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -127.7 Med: -4.6 Max: 51.5
Current: 51.5
During the past 6 years, Calidi Biotherapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 51.50% per year. The lowest was -127.70% per year. And the median was -4.60% per year.
CLDI's 3-Year OCF Growth Rate is ranked better than 86.24% of 1134
companies
in the Biotechnology industry
Industry Median: 17
vs CLDI: 51.50
Calidi Biotherapeutics Operating Cash Flow per Share Related Terms
Calidi Biotherapeutics Operating Cash Flow per Share Historical Data
* Premium members only.
The historical data trend for Calidi Biotherapeutics's Operating Cash Flow per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Calidi Biotherapeutics Operating Cash Flow per Share Chart
CLDI vs ARTL, CRIS, SXTP: Operating Cash Flow per Share Comparison
For the Biotechnology subindustry, Calidi Biotherapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Calidi Biotherapeutics Price-to-Operating-Cash-Flow vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Calidi Biotherapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Calidi Biotherapeutics's Price-to-Operating-Cash-Flow falls into.
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-34.45
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Operating Cash Flow per Share of $-34.45 mean?
Calidi Biotherapeutics (CLDI) has a Operating Cash Flow per Share of $-34.45 as of Jun. 2026. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on Calidi Biotherapeutics and its competitors. According to the industry distribution chart, Calidi Biotherapeutics ranks #156 out of 1134 companies in the Biotechnology industry, placing it in the top 13.8%.
Is Calidi Biotherapeutics' Operating Cash Flow per Share too high?
Calidi Biotherapeutics' current Operating Cash Flow per Share is $-34.45. Based on the distribution chart, Calidi Biotherapeutics ranks #156 out of 1134 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Calidi Biotherapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Calidi Biotherapeutics' Operating Cash Flow per Share compare to ARTL and CRIS?
According to the Biotechnology industry distribution chart, Calidi Biotherapeutics ranks #156 out of 1134 companies for Operating Cash Flow per Share. This places Calidi Biotherapeutics in the top 14% of its industry — outperforming the majority of peers. The industry median Operating Cash Flow per Share is 17.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Cash Flow per Share for a Biotechnology company?
The median Operating Cash Flow per Share among Biotechnology companies is 17.00, based on 1,134 companies in the industry. Companies in the top quartile (top 25%) have a Operating Cash Flow per Share significantly above this median, while those in the bottom quartile fall well below. However, Operating Cash Flow per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Cash Flow per Share mean?
A high Operating Cash Flow per Share can signal that a stock is expensive relative to its fundamentals. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on Calidi Biotherapeutics and its competitors. For the Biotechnology industry, the median Operating Cash Flow per Share is 17.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Calidi Biotherapeutics's current Operating Cash Flow per Share is $-34.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Calidi Biotherapeutics stock overvalued right now?
Calidi Biotherapeutics (CLDI) has a current Operating Cash Flow per Share of $-34.45. The current Operating Cash Flow per Share is $-34.45. Calidi Biotherapeutics' overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Cash Flow per Share calculated?
Operating Cash Flow per Share is calculated from a company's financial statements. For Calidi Biotherapeutics (CLDI), the current Operating Cash Flow per Share is $-34.45 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Calidi Biotherapeutics Inc is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company's proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. Its technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations. Its product candidates include The RedTail for Metastatic Solid Tumors, CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-101 (NeuroNova) for Newly Diagnosed High Grade Glioma.
11GF Score
Get the complete analysis for CLDI
Operating Cash Flow per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLDI has been successfully added to your 
